| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 |
8-K: Other Events
FAETH THERAPEUTICS PIKTOR Phase 2 Endometrial Cancer Topline Results NOVEMBER 9, 2026 Exhibit 99.1 |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer |
| 03 Nov 2026 |
Form 4: Parikh Anand Kiran, Director
Gave 100,000 shares as a gift · Acquired 100,000 shares (Gift) |
| 03 Nov 2026 | S-8 |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end |
| 03 Nov 2026 | 10-Q |
| 27 Oct 2026 |
Form 4: Schayowitz Adam, Director
Granted 25,000 Stock Option (right to buy) |
| 27 Oct 2026 |
Form 3: Schayowitz Adam, Director
No securities owned |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 17 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 15 Sep 2026 |
Form 4: Vousden Karen H, Director
Granted 25,000 Stock Option (right to buy) |
| 15 Sep 2026 |
Form 3: Vousden Karen H, Director
Holds 42,631 shares of Common Stock |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 144 |
| 04 Aug 2026 | 10-Q |
Loading...